Abstract 2389: Clinical and Prognostic Value of Advanced Glycation End-products (AGEs) in Chronic Heart Failure
tk;2 Introduction: Advanced glycation end-products (AGEs) have been proposed as a novel factor involved in the development and progression of chronic heart failure (CHF).
Hypothesis: We assessed the hypothesis that plasma levels of Nϵ-(carboxymethyl)lysine (CML) and Nϵ-(carboxyethyl)lysine (CEL), two well-known AGEs, are related to the severity and prognosis of CHF.
Methods: A total of 102 CHF patients, aged 58±12 year, with an average left ventricular ejection fraction of 28±9% were followed for 1.4[1.1–1.9] years. NYHA functional class and NT-pro-BNP were used as estimates of the severity of CHF. CML and CEL were determined by LC-MS/MS.
Results: Plasma CML levels were associated with NYHA functional class (P=0.006) and levels of NT-pro-BNP (P<0.001). Survival analysis performed for the combined end-point of death, heart transplantation, ischemic cardiovascular event (myocardial infarction or primary PTCA), and first hospitalization for heart failure, revealed that CML levels predicted outcome, even after correction for age and gender (HR 3.9 (2.0–7.6); p<0.001). CEL was not significantly associated with the severity of CHF and/or prognosis.
Conclusions: Plasma AGEs, in particular CML levels, are related to the severity and prognosis of CHF. This supports a possible pathophysiological relationship between AGE accumulation, and heart failure, which warrants further investigation.